Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This Phase I/II study will test the safety and anti-myeloma activity of ascending doses of
Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in
eligible patients with active multiple myeloma.